Pramipexole dihydrochloride hydrate Sexual Enhancement Powder CAS 191217-81-9 agonists
1,Product title:Pramipexole dihydrochloride hydrate
2, Product parameter table:
|Product Name||Pramipexole dihydrochloride hydrate|
|The molecular weight||302.264|
|boiling point||378ºC at 760 mmHg|
|point of flammability||182.4ºC|
3,Pramipexole dihydrochloride hydrate Description:
Pramipexole is a dopamine agonist belonging to the same class of drugs as Cabergoline. The primary purpose of this drug is in the treatment of Parkinson's disease. Pramipexole is most commonly found under the brand names Sifrol, Mirapexin and Mirapex, although generics are also available. Mirapex is the most well known brand by Boehringer Ingelheim Pharmaceuticals. Along with treating Parkinson's, Pramipexole is also prescribed for the treatment of restless legs syndrome. The drug has also shown promising signs in the treatment of bipolar depression, although it has never officially held this label.
Pramipexole is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) and restless legs syndrome (RLS).It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder. It is also being investigated for the treatment of clinical depression and fibromyalgia.
4,Pramipexole dihydrochloride hydrate use:
To alleviate the symptoms of Parkinson's disease: Parkinson's disease is due to the movement of brain dopaminergic neuron loss caused by dopamine deficiency, lead to patients with tremor, rigidity and bradykinesia and a series of symptoms. Hydrochloric acid highly selective effects on dopamine D2 and D3 receptor agonist, dopamine release, improve motor symptoms. Research on Shannon display, early Parkinson's disease patients pramipexole monotherapy after, can effectively control the motor symptoms in patients with early stage, to help maintain the ability of daily life. Pramipexole in combination with levodopa can effectively improve the ADL score and motor symptoms in patients with advanced Parkinson's disease score in patients with advanced Parkinson's disease, make life more vibrant.
Pramipexole is a dopamine agonist that directly correlates with the prolactin hormone. As dopamine levels in the body go up, prolactin levels go down. It does this by having a direct effect on the dopamine D3 receptor. Although it also acts on the D2 receptor its affinity for the D3 receptor is seven times greater than any existing dopamine agonist. The effect of Pramipexole on the D3 receptor has a strong impact on the neurological system, which is why it's used to treat Parkinson's disease and in some cases Alzheimer's disease. Through acting on the D3 receptor, Pramipexole also affects a man's sexual interest and activity.
Prolactin is in part directly responsible for a man's refractory period, which refers to the time it takes to recover from sexual activity so that performance can occur again. By lowering prolactin through an increase in dopamine, Pramipexole can directly reduce the refractory period resulting in the ability to perform sexually more frequently. Treating the signs and symptoms of Parkinson disease. It is also used to treat restless legs syndrome (RLS). It may also be used for other conditions as determined by your doctor. Pramipexole is a dopamine agonist. Exactly how pramipexole works is not known. It may increase the action of certain chemical receptors in the brain.
5, Pramipexole dihydrochloride hydrate contraindicated:
Breastfeeding is not allowed.
6, Pramipexole dihydrochloride hydrate Matters needing attention:
1. Use with caution in patients with renal insufficiency.
2. Can cause "sleep seizure", so drivers and machinery operators should pay special attention
7,Pramipexole dihydrochloride hydrate Adverse reactions:
Its adverse effects are similar to those of other dopamine receptor agonists, including nausea, dizziness, drowsiness and insomnia; Hallucinations, movement disorders, dry mouth, constipation, etc. [2-3]. At the beginning of treatment, postural hypotension is common.
8, Pramipexole dihydrochloride hydrate Expert review:
Praxol is a dopamine agonist that selectively acts on dopamine D3 (note, subscript) receptors. It can significantly reduce the tremor at rest in Parkinson's disease. The combination of levodopa with advanced Parkinson's disease reduced levodopa requirements and extended the time of optimal symptom control by an average of 2 hours per day. It has been reported that although pramexole can be used for the treatment of Parkinson's disease and its syndromes, its clinical efficacy is uncertain [2-3]